The Biopharmaceutics Classification System (BCS) and the Biopharmaceutics Drug Disposition Classification System (BDDCS): Beyond guidelines

The Biopharmaceutics Classification System (BCS) and the Biopharmaceutics Drug Disposition Classification System (BDDCS): Beyond guidelines

Publication: Int J Pharm
Software: GastroPlus®

The recent impact of the Biopharmaceutics Classification System (BCS) and the Biopharmaceutics Drug Disposition Classification System (BDDCS) on relevant scientific advancements is discussed.

Physiologically Based Pharmacokinetic Modeling to Evaluate Formulation Factors Influencing Bioequivalence of Metoprolol Extended‐Release Products

Physiologically Based Pharmacokinetic Modeling to Evaluate Formulation Factors Influencing Bioequivalence of Metoprolol Extended‐Release Products

Publication: J Clin Pharmacol
Software: DDDPlus™

The University of Florida Center for Pharmacometrics and Systems Pharmacology and the Food and Drug Administration Office of Generic Drugs have collaborated on a research project to develop...

Evaluating the Clinical Impact of Formulation Variability: A Metoprolol Extended‐Release Case Study

Evaluating the Clinical Impact of Formulation Variability: A Metoprolol Extended‐Release Case Study

Publication: J Clin Pharmacol

The objective of this research was to evaluate the impact of changes in the formulation of metoprolol extended‐release (ER) tablets on dissolution, pharmacokinetic, and exercise‐induced heart rate (EIHR) using...

Oxysterols and apolipoproteins in multiple sclerosis: a 5-year follow-up study

Oxysterols and apolipoproteins in multiple sclerosis: a 5-year follow-up study

Publication: J Lipid Res

The purpose of this work was to investigate whether changes in oxysterol and apolipoprotein levels over 5 years are associated with...

Discovery of Membrane Permeability, Pharmacokinetics Properties and Mechanism of Action for Analogs of Ethylenediamine-N,N′-di-2-(3-Cyclohexyl)Propionic Acid and 1,3-Propandiamine-N,N′-di-2-(3-Cyclohexyl)Propionic Acid with Antiproliferative Activity Using In Vitro and In Silico Methods

Discovery of Membrane Permeability, Pharmacokinetics Properties and Mechanism of Action for Analogs of Ethylenediamine-N,N′-di-2-(3-Cyclohexyl)Propionic Acid and 1,3-Propandiamine-N,N′-di-2-(3-Cyclohexyl)Propionic Acid with Antiproliferative Activity Using In Vitro and In Silico Methods

Publication: IFMBE Proc
Software: ADMET Predictor®
Division: PBPK

In previously in vitro studies on different cell lines and in vivo on melanoma and 4T1 murine breast cancer and metastasis it was shown antiproliferative activity for ester derivatives of (S,S)-ethylenediamine-N,N′-di-2-(3-cyclohexyl)propanoic acid, and (S,S)-1,3-propanediamine-N,N′-di-2-(3-cyclohexyl)propanoic acid.

Androgen Receptor and PI3K Pathway Activity in Ovarian Cancer

Androgen Receptor and PI3K Pathway Activity in Ovarian Cancer

Publication: Journal of Cancer Research and Therapeutic Oncology

We sought to evaluate androgen receptor (AR) and PI3K pathway activity in ovarian cancer cell lines and tissue and determine if either pathway was correlated with growth...

In Silico Prediction of Plasma Concentrations of Fluconazole Capsules with Different Dissolution Profiles and Bioequivalence Study Using Population Simulation

In Silico Prediction of Plasma Concentrations of Fluconazole Capsules with Different Dissolution Profiles and Bioequivalence Study Using Population Simulation

Publication: Pharmaceutics
Software: GastroPlus®

A biowaiver is accepted by the Brazilian Health Surveillance Agency (ANVISA) for immediate-release solid oral products containing Biopharmaceutics Classification System (BCS) class I drugs showing rapid drug dissolution.

The Discriminatory Power of the BCS-based Biowaiver: A Retrospective with Focus on Essential Medicines

The Discriminatory Power of the BCS-based Biowaiver: A Retrospective with Focus on Essential Medicines

Publication: J Pharm Sci
Software: GastroPlus®

This article summarizes historic developments, recent expert opinions and (currently) unresolved challenges concerning the Biopharmaceutics Classification System (BCS) based biowaiver.

Analysis of pharmacological mechanisms and targets mining of Wuzi-Yanzong-Wan for treating non-obstructive oligoasthenospermia

Analysis of pharmacological mechanisms and targets mining of Wuzi-Yanzong-Wan for treating non-obstructive oligoasthenospermia

Publication: Biomed Pharmacother
Software: MedChem Studio™

As a classical traditional Chinese medicine, Wuzi-Yanzong-Wan (WZYZW) has been widely applied for several centuries to treat non-obstructive oligoasthenozoospermia (NOA), although its pharmacological mechanisms remain largely unknown.

Quantitative Analysis of Tozadenant Using Liquid Chromatography-Mass Spectrometric Method in Rat Plasma and Its Human Pharmacokinetics Prediction Using Physiologically Based Pharmacokinetic Modeling

Quantitative Analysis of Tozadenant Using Liquid Chromatography-Mass Spectrometric Method in Rat Plasma and Its Human Pharmacokinetics Prediction Using Physiologically Based Pharmacokinetic Modeling

Publication: Molecules

Tozadenant is one of the selective adenosine A2a receptor antagonists with a potential to be a new Parkinson’s disease (PD) therapeutic drug. In this study, a liquid chromatography-massspectrometry ...

Cu-mediated synthesis of differentially substituted diazepines as AChE inhibitors; validation through molecular docking and Lipinski’s filter to develop novel anti-neurodegenerative drugs

Cu-mediated synthesis of differentially substituted diazepines as AChE inhibitors; validation through molecular docking and Lipinski’s filter to develop novel anti-neurodegenerative drugs

Publication: Bioorg Med Chem

A highly efficient Cu-mediated route for the synthesis of fused [1,2,3]triazolo[1,4]diazepines has been developed by azidation-cyclization of 2-bromo-N-propargylamines in a one-pot fashion.

In silico methods for development of generic drug‐device combination orally inhaled drug products

In silico methods for development of generic drug‐device combination orally inhaled drug products

Publication: CPT Pharmacometrics Syst Pharmacol
Software: GastroPlus®

Development of generic single‐entity drug‐device combination products for orally inhaled drug products (OIDPs) is challenging, due in part to the complex nature of device design characteristics, and to the...

Predicting pK a for Small Molecules on Public and In‐house Datasets Using Fast Prediction Methods Combined with Data Fusion

Predicting pK a for Small Molecules on Public and In‐house Datasets Using Fast Prediction Methods Combined with Data Fusion

Publication: Mol Inform
Software: ADMET Predictor®

Data fusion approach was investigated in the context of pKa prediction for 391 small molecules derived from a public data source as well as for 681 compounds from an internal corporate database.

In-silico and In-vitro Drug Analysis of Selected Flavonoids, Including Fusarochromanone

In-silico and In-vitro Drug Analysis of Selected Flavonoids, Including Fusarochromanone

Authors: Stratton CA
Publication: Louisiana State University in Shreveport
Software: ADMET Predictor®

In recent years, there has been a shift in the pre-clinical drug discovery paradigm from a strict in-vitro process toward an in-silico based process.

Supporting systems science through in silico applications: A focus on informing metabolic mechanisms

Supporting systems science through in silico applications: A focus on informing metabolic mechanisms

Authors: Leonard JA
Publication: Current Opinion in Toxicology
Software: ADMET Predictor®

Despite the advent of new in silico methodologies to characterize exposure and pharmacokinetic properties of environmental chemicals, numerous limitations remain in the understanding and predicting of metabolic processes.